(Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity

Figure 1

hMSC treatment in ATG immunosuppressed and cisplatin-treated BALB/cOlaHsd male mice 3 months after transplantation revealed unexpected pathology. (a) Subpleuraly, a homogeneous solid tumor (diameter 0.5 mm) with rare mitosis and uniform nuclei was sharply demarcated from the surrounding tissue in the lung of hMSC treated mouse (HE, magnification 100x). (b) Inflammatory cells (lymphocytes, plasma cells, and histiocytes) surrounding the arteriola and vein in the kidney of the hMSC-treated mouse (PAS, magnification 200). (c) Thrombus in the small artery of the right ventricle wall of ATG + cisplatin-treated mouse (HE, magnification 400x). (d) Moderate chronic jejunitis in hMSC-treated mouse—note atrophy of crypts and loss of architecture of villi (Kreyberg, magnification 400x). (e) Jejunum in the healthy untreated mouse (Kreyberg, magnification 400x). (f) Jejunum of the cisplatin-treated mouse. Restitution of the mucosa is seen; however, the height of villi is decreased compared to healthy mice (Kreyberg, magnification 400x).

(a)

(b)

(c)

(d)

(e)

(f)